Founded 1978


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 24
Average round size
The average size of a deal this fund participated in
Portfolio companies 19
Rounds per year 0.56
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Health Diagnostics
  • Medical
  • Personal Health

LabCorp is the famous Corporate Investor, which was founded in 1976. The main office of represented Corporate Investor is situated in the Burlington. The venture was found in North America in United States.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Cloud Computing, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Flatiron Health, ORIG3N, Navigating Cancer.

The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2019. The high activity for fund was in 2019. Opposing the other organizations, this LabCorp works on 22 percentage points less the average amount of lead investments. Speaking about the real fund results, this Corporate Investor is 0 percentage points less often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. When the investment is from LabCorp the average startup value is 10-50 millions dollars.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the LabCorp, startups are often financed by General Catalyst, Hatteras Venture Partners, 180 Degree Capital. The meaningful sponsors for the fund in investment in the same round are Hatteras Venture Partners, GV, DEFTA Partners. In the next rounds fund is usually obtained by The Kraft Group, Spectrum Health Ventures, Hatteras Venture Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of LabCorp:
Typical Co-investors
LabCorp is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after LabCorp:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Digitech Venture Capital Fund United States, Houston
Archipelago Advisa Investment Indonesia, Surakarta
BDC Capital - Cleantech Practice Canada, Calgary
West Deutsche Landesbank Girozentrale Germany, Düsseldorf
Cubo Capital Mexico, Mexico City
Concert Capital Partners Spain, Madrid
National Cancer Institute United States, Bethesda
Profin Capital -
Qu Ventures -
Capital Now -
Grow Tech Labs Canada, Vancouver
Tuniu China, Nanjing
Xiamen Science & Technology Industrial Group China, Xiamen
BHP Australia, Melbourne
Jennings Capital Inc Canada, Calgary
GW Holdings LLC United States, Paradise Valley
Global Excel Management Inc. Canada, Sherbrooke
Cleantech Open United States, Palo Alto
Alter Venture Partners Luxembourg, Luxembourg
Tyler Florence Group United States, Mill Valley

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation


Clinical Trials
Supply Chain Management
03 Mar 2021 United Kingdom, Cardiff

Circuit Clinical

Clinical Trials
Product Research
Social Network
$7M02 Mar 2021 United States, Buffalo


Health Care
Information Services
Information Technology
$5M09 Apr 2020 United States, Washington


Health Care
Health Diagnostics
$15M04 Nov 2019 United States, Boston

Navigating Cancer

Health Care
$26M17 Sep 2019 United States, Seattle

Boston MicroFluidics

Health Care
Medical Device
$17M27 Aug 2019 United States, Boston

Sandstone Diagnostics

Health Care
Medical Device
$2M06 May 2019 United States, " United States"}


Health Diagnostics
Life Science
$3M01 May 2019 United States, Greenville

Mission Bio

Health Care
$30M13 Dec 2018 United States, San Francisco
TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round

– TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH).
– These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.
– The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics

– Presage Biosciences closed a $13m financing and commenced new research collaborations with Merck and Maverick Therapeutics.
– The financing includes $7m raised from new investors, including the LabCorp Venture Fund, Bristol Myers Squibb, and InHarv Partners Ltd.
– An additional $6m convertible note from Takeda Ventures will convert to equity.
– The proceeds from this financing will support expansion of Presage’s existing network of clinical sites in the U.S. and Australia, as well as development of next-generation CIVO microdose injection devices designed to access a wider spectrum of cancers.
– Presage has pioneered a new approach to early evaluation of investigational cancer drugs and combinations in clinical trials with a technology that enables detailed assessment of multiple drugs simultaneously in patients with solid tumors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LabCorp?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: